| Business Summary | | AutoImmune
Inc.
is
a
biopharmaceutical
company
developing
a
class
of
therapeutics
for
the
treatment
of
autoimmune
and
other
cell-mediated
inflammatory
diseases
and
conditions.
Based
on
pre-clinical
and
clinical
data,
the
Company's
proprietary
approach
to
therapy
may
induce
tissue-specific
immunosuppression
without
toxicity
or
significant
side
effects.
All
of
the
Company's
products
are
based
upon
the
principles
of
mucosal
tolerance.
When
proteins
are
administered
by
a
mucosal
route
(oral,
nasal
or
by
aerosol
to
the
lungs),
the
body's
natural
immune
system
mechanisms
suppress
the
response
that
would
otherwise
arise
against
a
foreign
substance.
This
immune
suppression
can
be
directed
toward
a
specific
tissue
through
appropriate
selection
and
dosing
of
the
protein
in
a
mucosally
delivered
product. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | AutoImmune
Inc.
is
a
biopharmaceutical
company
developing
a
new
class
of
orally
administered
pharmaceutical
products
for
the
treatment
of
autoimmune
and
other
cell-mediated
inflammatory
diseases
and
conditions.
For
the
six
months
ended
6/30/01,
revenues
totaled
$15
thousand,
down
from
$4
million.
Net
loss
totaled
$192
thousand
vs.
an
income
of
$3.4
million.
Results
reflect
the
absence
of
initial
payments
for
certain
patent
rights
and
lower
operating
margins. | More
from
Market Guide: Significant
Developments |
| | | Robert
C. Bishop
Ph.D.,
Chmn./Pres./CEO Fredric
G. Bader
Ph.D.,
VP Heather
A. Ellerkamp,
Treas. Constantine
Alexander,
Secy. | More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|